Overcoming therapy resistance in EGFR-mutant lung cancer
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy
The identification of molecular agents inhibiting specific functions in cancer cells
progression is considered as one of the most successful plans in cancer treatment. The …
progression is considered as one of the most successful plans in cancer treatment. The …
Targeting acquired and intrinsic resistance mechanisms in epidermal growth factor receptor mutant non-small-cell lung cancer
MP Shah, JW Neal - Drugs, 2022 - Springer
Over the past 2 decades, rapid advances in molecular profiling and the development of
targeted therapies have dramatically improved the clinical course of advanced non-small …
targeted therapies have dramatically improved the clinical course of advanced non-small …
The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies
C Laface, FM Maselli, AN Santoro, ML Iaia, F Ambrogio… - Pharmaceutics, 2023 - mdpi.com
Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
Current approaches in NSCLC targeting K-RAS and EGFR
V Aran, J Omerovic - International journal of molecular sciences, 2019 - mdpi.com
The research and treatment of non-small cell lung cancer (NSCLC) have achieved some
important advances in recent years. Nonetheless, the overall survival rates for NSCLC …
important advances in recent years. Nonetheless, the overall survival rates for NSCLC …
Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
D Reita, L Pabst, E Pencreach, E Guérin, L Dano… - Cancers, 2021 - mdpi.com
Simple Summary Non-small cell lung cancer (NSCLC) is the most common cancer in the
world. For common EGFR mutations, treatment is based on different inhibitors. Despite the …
world. For common EGFR mutations, treatment is based on different inhibitors. Despite the …
Next generation sequencing-based profiling of cell free DNA in patients with advanced non-small cell lung cancer: advantages and pitfalls
R Esposito Abate, D Frezzetti, MR Maiello, M Gallo… - Cancers, 2020 - mdpi.com
Simple Summary Genomic profiling of non-small cell lung cancer (NSCLC) patients offers
the possibility of therapeutic intervention with target-based agents. The analysis of …
the possibility of therapeutic intervention with target-based agents. The analysis of …
Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions,“uncommon-G719X, S768I, L861Q”) Among the …
SS Zhang, SI Ou - Lung Cancer: Targets and Therapy, 2022 - Taylor & Francis
Abstract Osimertinib, a third-generation (3G) epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) is now considered the standard of care for the first-line (1L) …
tyrosine kinase inhibitor (TKI) is now considered the standard of care for the first-line (1L) …
Recent advances in epidermal growth factor receptor inhibitors (EGFRIs) and their role in the treatment of cancer: a review
A Unnisa, AK Chettupalli, T Hussain… - Anti-Cancer Agents in …, 2022 - ingentaconnect.com
Tyrosine kinases are known to play a role in tumour growth and proliferation, and they have
become common drug targets. Tyrosine kinase inhibitors (TKIs) prohibit associated kinases …
become common drug targets. Tyrosine kinase inhibitors (TKIs) prohibit associated kinases …
[HTML][HTML] Role of circulating tumor cell spheroids in drug resistance
G Hamilton, B Rath - Cancer Drug Resistance, 2019 - ncbi.nlm.nih.gov
Cancer cell spheroids are used for drug screening as these three-dimensional (3D)
assemblies recapitulate tumors more realistic than the widely employed 2D in vitro cultures …
assemblies recapitulate tumors more realistic than the widely employed 2D in vitro cultures …